Despite these clinical benefits, chronic therapy with ruxolitinib has not led to molecular or pathologic remissions in the majority of MPN patients [7, 8] in contrast to ABL kinase inhibitors in chronic myeloid leukemia (CML). Here, ABL1 is linked to myeloproliferative disorder.